Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130]
1 Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
2 Department of Medical Oncology, Gustave Roussy, Villejuif, France.
3 Biostatistics and Epidemiology Unit, Gustave Roussy, Paris-Saclay University, CESP, INSERM, Medicine University Paris-Sud, Villejuif, France.
4 Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
5 Laboratory of Translational Research and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy, France; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.
6 Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.
7 Department of Interventional Radiology, Gustave Roussy, Villejuif, France.
8 Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; U981 INSERM, Laboratory for Predictive Biomarkers and New Therapeutic Strategies in Oncology, Gustave Roussy, Villejuif, France.
9 Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France. Electronic address: antoine.hollebecque@gustaveroussy.fr.